OTCMKTS:MATN - OXiGENE Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2061 -0.02 (-10.00 %)
(As of 05/24/2018 04:00 PM ET)
Previous Close$0.2290
Today's Range$0.20 - $0.2290
52-Week Range$0.0901 - $0.6499
Volume19,995 shs
Average Volume51,418 shs
Market Capitalization$9.10 million
P/E Ratio-0.40
Dividend YieldN/A
Beta2.12

About OXiGENE (OTCMKTS:MATN)

OXiGENE logoMateon Therapeutics, Inc., a biopharmaceutical company, focuses on the development of vascular disrupting agents for the treatment of cancer in the United States. Its principal clinical stage product includes fosbretabulin tromethamine, a reversible tubulin binding agent, which has completed Phase II clinical trial for treating recurrent ovarian cancer; and in Phase II clinical trial for treating neuroendocrine tumors. The company also develops OXi4503 that is in Phase I/II clinical trial stage for treating patients with relapsed or refractory acute myelogenous leukemia or myelodysplastic syndromes. The company was formerly known as OXiGENE, Inc. and changed its name to Mateon Therapeutics, Inc. in June 2016. Mateon Therapeutics, Inc. was founded in 1988 and is headquartered in South San Francisco, California.

Receive MATN News and Ratings via Email

Sign-up to receive the latest news and ratings for MATN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:MATN
CUSIPN/A
Phone650-635-7000

Debt

Debt-to-Equity RatioN/A
Current Ratio0.26
Quick Ratio0.26

Price-To-Earnings

Trailing P/E Ratio-0.40
Forward P/E Ratio-1.15
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value($0.03) per share
Price / Book-6.87

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-13,810,000.00
Net MarginsN/A
Return on Equity-802.11%
Return on Assets-384.06%

Miscellaneous

Employees5
Outstanding Shares41,420,000

OXiGENE (OTCMKTS:MATN) Frequently Asked Questions

What is OXiGENE's stock symbol?

OXiGENE trades on the OTCMKTS under the ticker symbol "MATN."

How were OXiGENE's earnings last quarter?

OXiGENE, Inc. (OTCMKTS:MATN) released its quarterly earnings data on Monday, May, 14th. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. View OXiGENE's Earnings History.

What price target have analysts set for MATN?

2 brokerages have issued 1-year price targets for OXiGENE's stock. Their predictions range from $1.00 to $1.00. On average, they expect OXiGENE's stock price to reach $1.00 in the next twelve months. View Analyst Ratings for OXiGENE.

What are Wall Street analysts saying about OXiGENE stock?

Here are some recent quotes from research analysts about OXiGENE stock:
  • 1. According to Zacks Investment Research, "Mateon Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents for the treatment of cancer. Its product pipeline consists of VDAs-CA4P and OXi4503, which are in preclinical trail stage. Mateon Therapeutics, Inc., formerly known as OXiGENE, Inc., is based in SOUTH SAN FRANCISCO, United States. " (4/21/2018)
  • 2. Maxim Group analysts commented, "Mateon announced that the P1b/2 trial (investigator-sponsored) evaluating the company’s lead combretastatin, CA4P, in combination with pazopanib (tyrosine kinase inhibitor, TKI) in recurrent ovarian cancer has been stopped (for now) as serious adverse events (SAEs) have emerged." (6/7/2017)

Who are some of OXiGENE's key competitors?

Who are OXiGENE's key executives?

OXiGENE's management team includes the folowing people:
  • Dr. William D. Schwieterman M.D., Chairman, Chief Exec. Officer and Pres (Age 60)
  • Mr. Matthew M. Loar, Chief Financial Officer (Age 55)
  • Dr. David John Chaplin B.Sc, M.Sc, Ph.D., Chief Scientific Officer and Director (Age 62)
  • Ms. Shari Annes, Exec. Officer of Investor Relations
  • Dr. Yuval Binur Ph.D., Exec. VP of Financial

Has OXiGENE been receiving favorable news coverage?

News stories about MATN stock have trended positive recently, Accern reports. The research group identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OXiGENE earned a news impact score of 0.29 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 47.04 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of OXiGENE?

Shares of MATN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is OXiGENE's stock price today?

One share of MATN stock can currently be purchased for approximately $0.2061.

How big of a company is OXiGENE?

OXiGENE has a market capitalization of $9.10 million. The biopharmaceutical company earns $-13,810,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. OXiGENE employs 5 workers across the globe.

How can I contact OXiGENE?

OXiGENE's mailing address is 701 GATEWAY BLVD SUITE 210, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-635-7000 or via email at [email protected]


MarketBeat Community Rating for OXiGENE (MATN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  116 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  215
MarketBeat's community ratings are surveys of what our community members think about OXiGENE and other stocks. Vote "Outperform" if you believe MATN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MATN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

OXiGENE (OTCMKTS:MATN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for OXiGENE in the last 12 months. Their average twelve-month price target is $1.00, suggesting that the stock has a possible upside of 385.20%. The high price target for MATN is $1.00 and the low price target for MATN is $1.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.752.75
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.00$1.50$1.75$1.75
Price Target Upside: 385.20% upside528.14% upside651.07% upside651.07% upside

OXiGENE (OTCMKTS:MATN) Consensus Price Target History

Price Target History for OXiGENE (OTCMKTS:MATN)

OXiGENE (OTCMKTS:MATN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/18/2018HC WainwrightSet Price TargetBuy$1.00View Rating Details
8/1/2017Maxim GroupReiterated RatingHoldView Rating Details
4/20/2017Roth CapitalInitiated CoverageBuy ➝ Buy$2.00View Rating Details
3/13/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$2.00View Rating Details
(Data available from 5/24/2016 forward)

Earnings

OXiGENE (OTCMKTS:MATN) Earnings History and Estimates Chart

Earnings by Quarter for OXiGENE (OTCMKTS:MATN)

OXiGENE (OTCMKTS:MATN) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.18 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS

OXiGENE (OTCMKTS MATN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/14/2018Q1 2018($0.04)($0.03)ViewN/AView Earnings Details
4/16/2018Q4 2017($0.09)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.13)ViewN/AView Earnings Details
8/2/2017Q2 2017($0.12)($0.15)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.1330)($0.15)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.13)($0.13)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.15)($0.12)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.14)ViewN/AView Earnings Details
5/9/2016Q116($0.19)($0.13)ViewN/AView Earnings Details
3/28/2016Q4 2015($0.14)($0.15)ViewN/AView Earnings Details
11/10/2015Q3($0.13)($0.14)ViewN/AView Earnings Details
8/4/2015Q215($0.10)($0.13)ViewN/AView Earnings Details
4/30/2015Q115($0.13)($0.13)ViewN/AView Earnings Details
4/14/2015($0.13)($0.11)ViewN/AView Earnings Details
3/17/2015Q414($0.17)($0.11)ViewN/AView Earnings Details
11/12/2014Q3($0.23)($0.17)ViewListenView Earnings Details
8/5/2014Q2 2014($0.13)($0.23)ViewN/AView Earnings Details
5/6/2014Q1 2014($0.19)($0.29)ViewN/AView Earnings Details
3/18/2014Q412($4.67)ViewN/AView Earnings Details
11/12/2013Q3($1.88)$0.10 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.74)ViewN/AView Earnings Details
5/6/2013Q1 2013($0.97)ViewN/AView Earnings Details
3/12/2013Q4 2012($0.92)ViewN/AView Earnings Details
11/8/2012Q312($0.13)ViewN/AView Earnings Details
8/8/2012Q2 2012($1.64)ViewN/AView Earnings Details
5/9/2012Q1 2012($1.44)ViewN/AView Earnings Details
3/13/2012Q4 2011($1.39)ViewN/AView Earnings Details
11/9/2011Q3 2011($3.12)($2.03)ViewN/AView Earnings Details
8/10/2011Q2 2011($5.52)($3.87)ViewN/AView Earnings Details
5/12/2011Q1 2011($6.60)($1.58)ViewN/AView Earnings Details
11/4/2010Q3 2010($24.01)($41.78)ViewN/AView Earnings Details
8/12/2010Q2 2010($21.61)($17.29)ViewN/AView Earnings Details
5/11/2010Q1 2010($26.41)($39.14)ViewN/AView Earnings Details
2/25/2010Q4 2009($31.21)($28.57)ViewN/AView Earnings Details
11/9/2009Q3 2009($28.81)($68.43)ViewN/AView Earnings Details
7/30/2009Q2 2009($33.61)($26.41)ViewN/AView Earnings Details
5/11/2009Q1 2009($33.61)($29.05)ViewN/AView Earnings Details
3/19/2009Q4 2008($38.42)($32.89)ViewN/AView Earnings Details
11/5/2008Q3 2008($48.02)($59.30)ViewN/AView Earnings Details
8/4/2008Q2 2008($52.82)($59.78)ViewN/AView Earnings Details
5/5/2008Q1 2008($50.42)($46.58)ViewN/AView Earnings Details
2/28/2008Q4 2007($48.02)($49.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

OXiGENE (OTCMKTS:MATN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

OXiGENE (OTCMKTS MATN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.60%
Insider Trading History for OXiGENE (OTCMKTS:MATN)

OXiGENE (OTCMKTS MATN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2016Donald Rogers ReynoldsDirectorBuy30,000$0.35$10,500.0012,700View SEC Filing  
6/28/2013Peter LangeckerCEOBuy3,000$2.75$8,250.00View SEC Filing  
6/25/2013Peter LangeckerCEOBuy2,000$2.79$5,580.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

OXiGENE (OTCMKTS MATN) News Headlines

Source:
DateHeadline
Financial Contrast: OXiGENE (MATN) versus The CompetitionFinancial Contrast: OXiGENE (MATN) versus The Competition
www.americanbankingnews.com - May 20 at 9:53 AM
Critical Contrast: OXiGENE (MATN) vs. Cellular Biomedicine Gr (CBMG)Critical Contrast: OXiGENE (MATN) vs. Cellular Biomedicine Gr (CBMG)
www.americanbankingnews.com - May 17 at 11:15 PM
Analyzing OXiGENE (MATN) and Its RivalsAnalyzing OXiGENE (MATN) and Its Rivals
www.americanbankingnews.com - May 15 at 12:29 PM
OXiGENE (MATN) Announces Quarterly  Earnings Results, Beats Estimates By $0.01 EPSOXiGENE (MATN) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 15 at 9:46 AM
Mateon Therapeutics Reports First Quarter 2018 Financial ResultsMateon Therapeutics Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 14 at 10:02 AM
Contrasting OXiGENE (MATN) and Its PeersContrasting OXiGENE (MATN) and Its Peers
www.americanbankingnews.com - May 10 at 11:19 PM
OXiGENE (MATN) vs. Its Peers Critical AnalysisOXiGENE (MATN) vs. Its Peers Critical Analysis
www.americanbankingnews.com - May 7 at 8:06 AM
OXiGENE (MATN) & Its Rivals Critical AnalysisOXiGENE (MATN) & Its Rivals Critical Analysis
www.americanbankingnews.com - May 3 at 9:01 PM
OXiGENE (MATN) Rating Increased to Sell at ValuEngineOXiGENE (MATN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - May 3 at 12:39 AM
OXiGENE (MATN) vs. Its Competitors Head to Head ContrastOXiGENE (MATN) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - May 1 at 5:10 PM
Comparing OXiGENE (MATN) and Its CompetitorsComparing OXiGENE (MATN) and Its Competitors
www.americanbankingnews.com - May 1 at 9:22 AM
OXiGENE (MATN) Lifted to "Buy" at Zacks Investment ResearchOXiGENE (MATN) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 21 at 7:24 AM
OXiGENE (MATN) Earns Buy Rating from HC WainwrightOXiGENE (MATN) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - April 18 at 9:00 AM
Mateon Therapeutics Provides Business Update and Reports 2017 Financial ResultsMateon Therapeutics Provides Business Update and Reports 2017 Financial Results
finance.yahoo.com - April 17 at 9:39 AM
Mateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing TransactionMateon Therapeutics Raises Net Proceeds of Approximately $2.4 Million in Financing Transaction
finance.yahoo.com - April 16 at 4:33 PM
Contrasting Agenus (AGEN) and OXiGENE (MATN)Contrasting Agenus (AGEN) and OXiGENE (MATN)
www.americanbankingnews.com - April 8 at 11:21 PM
Zacks.com featured highlights: Mateon Therapeutics, Emerge Energy Services, Cobalt International Energy and InpixonZacks.com featured highlights: Mateon Therapeutics, Emerge Energy Services, Cobalt International Energy and Inpixon
finance.yahoo.com - April 1 at 9:22 AM
Mateon Therapeutics (MATN) & Soligenix (SNGX) Head-To-Head AnalysisMateon Therapeutics (MATN) & Soligenix (SNGX) Head-To-Head Analysis
www.americanbankingnews.com - March 8 at 4:13 PM
Mateon Therapeutics (MATN) versus Soligenix (SNGX) Head to Head ContrastMateon Therapeutics (MATN) versus Soligenix (SNGX) Head to Head Contrast
www.americanbankingnews.com - February 8 at 9:22 PM
Mateon Therapeutics (MATN) versus Tetralogic Pharmaceuticals (TLOG) Financial AnalysisMateon Therapeutics (MATN) versus Tetralogic Pharmaceuticals (TLOG) Financial Analysis
www.americanbankingnews.com - January 16 at 5:08 PM
Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in ... - GlobeNewswire (press release)Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in ... - GlobeNewswire (press release)
globenewswire.com - January 8 at 5:25 PM
Mateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint InhibitorsMateon Announces New Preclinical Data Demonstrating Enhanced Tumor Immune Responses when CA4P is Given in Combination with Checkpoint Inhibitors
finance.yahoo.com - January 8 at 9:53 AM
Mateon Therapeutics to Present at the 2018 Biotech Showcase - GlobeNewswire (press release)Mateon Therapeutics to Present at the 2018 Biotech Showcase - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:06 PM
Mateon Therapeutics to Present at the 2018 Biotech ShowcaseMateon Therapeutics to Present at the 2018 Biotech Showcase
finance.yahoo.com - January 3 at 8:41 AM
Mateon Therapeutics (MATN) vs. Mirati Therapeutics (MRTX) Head to Head SurveyMateon Therapeutics (MATN) vs. Mirati Therapeutics (MRTX) Head to Head Survey
www.americanbankingnews.com - December 30 at 3:16 PM
Analyzing Grifols SA, Barcelona (GRFS) and Mateon Therapeutics (MATN)Analyzing Grifols SA, Barcelona (GRFS) and Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 28 at 11:40 AM
Mateon Therapeutics (MATN) versus Trillium Therapeutics (TRIL) Critical SurveyMateon Therapeutics (MATN) versus Trillium Therapeutics (TRIL) Critical Survey
www.americanbankingnews.com - December 25 at 3:26 PM
Financial Comparison: Jazz Pharmaceuticals (JAZZ) vs. Mateon Therapeutics (MATN)Financial Comparison: Jazz Pharmaceuticals (JAZZ) vs. Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 22 at 9:20 PM
Analyzing Trillium Therapeutics (TRIL) & Mateon Therapeutics (MATN)Analyzing Trillium Therapeutics (TRIL) & Mateon Therapeutics (MATN)
www.americanbankingnews.com - December 7 at 7:28 PM
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor - GlobeNewswire (press release)Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor - GlobeNewswire (press release)
globenewswire.com - December 5 at 5:15 PM
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint InhibitorMateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
finance.yahoo.com - December 5 at 10:12 AM
Critical Contrast: Mateon Therapeutics (MATN) and XOMA (XOMA)Critical Contrast: Mateon Therapeutics (MATN) and XOMA (XOMA)
www.americanbankingnews.com - November 30 at 9:30 AM
Financial Contrast: Mateon Therapeutics (MATN) versus Anavex Life Sciences Corp. (AVXL)Financial Contrast: Mateon Therapeutics (MATN) versus Anavex Life Sciences Corp. (AVXL)
www.americanbankingnews.com - November 23 at 3:14 PM
HC Wainwright Reiterates Buy Rating for Mateon Therapeutics, Inc. (MATN)HC Wainwright Reiterates Buy Rating for Mateon Therapeutics, Inc. (MATN)
www.americanbankingnews.com - November 22 at 4:26 PM
Mateon Therapeutics, Inc. (MATN) Posts Quarterly  Earnings ResultsMateon Therapeutics, Inc. (MATN) Posts Quarterly Earnings Results
www.americanbankingnews.com - November 15 at 2:01 PM
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 15 at 6:13 AM
Mateon Provides Corporate Update and Reports Third Quarter 2017 Financial ResultsMateon Provides Corporate Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 15 at 6:13 AM

SEC Filings

OXiGENE (OTCMKTS:MATN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

OXiGENE (OTCMKTS:MATN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

OXiGENE (OTCMKTS MATN) Stock Chart for Thursday, May, 24, 2018

Loading chart…

This page was last updated on 5/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.